| Literature DB >> 35459251 |
Ying Zhang1, Huan Zhou1, Zhou Ting Tuo1, Jinyou Wang1, Chenyu Sun2, Liangkuan Bi3.
Abstract
BACKGROUND: Bladder cancer is one of the most common genitourinary cancers. Traditional transperitoneal radical cystectomy is the gold standard treatment for muscle-invasive bladder cancer. Our study was to compare the perioperative and oncological outcomes of extraperitoneal laparoscopic radical cystectomy (ELRC) with intracorporeal neobladder versus transperitoneal urinary diversion for bladder cancer.Entities:
Keywords: Bladder cancer; Extraperitoneal; Intracorporeal urinary diversion; Laparoscopic radical cystectomy; Laparoscopy; Radical cystectomy; Surgical technique; Transperitoneal; Urinary diversion
Mesh:
Year: 2022 PMID: 35459251 PMCID: PMC9034519 DOI: 10.1186/s12957-022-02587-1
Source DB: PubMed Journal: World J Surg Oncol ISSN: 1477-7819 Impact factor: 3.253
Fig. 1A 4 cm infraumbilical skin incision to enter the extraperitoneal space. B An artificial gasbag was inserted and injected with air inflation of 700–1000 ml to expand the extraperitoneal operation space. C The trocars (12 mm and 5 mm) location
Fig. 2A Whole pelvic fatty tissue was gently pushed with ultrasonic knife. B Vas deferens were cut off. C The left space of the bladder was fully freed. D PLND of the left side. E Cutting off the left ureter. F Resection of urethra and prostate. G Pelvic view after RC. H Resecting the bladder in vitro. I The beginning of reconstruction of intracorporeal ileal neobladder
Baseline and perioperative demographic data
| Characteristic | ELRC group ( | TLRC group ( | |
|---|---|---|---|
| Age year, median ± SD (range) | 67.8 ± 8.4 | 66.0 ± 8.9 | 0.283c |
| BMI kg/m2, median ± SD (range) | 25.5 ± 3.6 | 26.2 ± 3.6 | 0.313c |
| ASA score ≥ 2, no. (%) | 25(52.1) | 38(58.5) | 0.567a |
| Previous abdominal surgery, no. (%) | 13 (27.1) | 20 (30.8) | 0.835a |
| 0.563a | |||
| Ta Tis | 5 (10.4) | 9 (13.8) | |
| T1 | 16 (33.3) | 26 (40.0) | |
| T2 | 27 (56.3) | 30 (46.2) | |
| TUR-BT, | 23 (47.9) | 38 (58.5) | 0.340a |
| New adjuvant chemotherapy, | 14 (29.2) | 21 (32.3) | 0.837a |
| Operative time, median ± SD, min | 286.5 ± 34.5 | 272.1 ± 35.5 | |
| Estimated blood loss, mean ± SD, mL | 405.2 ± 173.3 | 383.0 ± 180.0 | 0.517c |
| Transfusion rate, no. (%) | 3(6.3) | 5(7.7) | 0.999b |
| Interval to flatus, mean ± SD, h | 35.5 ± 9.7 | 42.7 ± 10.8 | |
| Interval to solid food, mean ± SD, day | 4.8 ± 1.3 | 6.0 ± 1.7 | |
| Length of hospital stay, mean± SD, day | 12.7 ± 2.0 | 14.0 ± 2.7 |
aPearson chi-square test
bFisher exact test
cIndependent t test
Comparison of early complications in ELRC group versus TLRC group
| Early complications | ELRC group ( | TLRC group (n = 65) | |
|---|---|---|---|
| Over all complication rate (at least one) | 15 (31.3%) | 31 (47.7%) | 0.0856b |
| Major complication (grade 3–5) | 5 (10.4%) | 9 (13.8%) | 0.774b |
| 1 (2.1%) | 10 (14.9%) | ||
| No stool until postoperative day 7 | 1 | 6 | |
| Ulcer or gastrointestinal bleeding | 0 | 3 | |
| Intestinal fistula and peritonitis (reoperation) | 0 | 1 | |
| 4 (8.3%) | 7 (10.8%) | 0.757b | |
| Wound infection | 2 | 4 | |
| Pneumonia | 2 | 3 | |
| 4 (8.3%) | 5 (7.7%) | 0.999b | |
| Urinary tract infection | 1 | 2 | |
| Urine leakage | 1 | 1 | |
| Pyelonephritis | 0 | 1 | |
| Renal failure | 2 | 1 | |
| 3 (6.3%) | 2 (3.1%) | 0.649b | |
| 1 (2.1%) | 3 (4.6%) | 0.636b | |
| 2 (4.2%) | 2 (3.1%) | 0.999b | |
| 0 (0) | 1 (1.5%) | 0.999b | |
| 2 (4.2%) | 3 (4.6%) | 0.999b | |
| Deep leg vein thrombosis | 1 | 3 | |
| Pulmonary embolism | 1 | 0 | |
| 0(0) | 0(0) | 0.999b |
aPearson chi-square test
bFisher exact test
cIndependent t test
Comparison of late complications in ELRC group versus TLRC group
| Late complications | ELRC group ( | TLRC group ( | |
|---|---|---|---|
| Over all complication rate (at least one) | 13 (27.1%) | 22 (33.8%) | 0.538b |
| Major complications (grade 3–5) | 5 (10.4%) | 11 (16.9%) | 0.418b |
| 0.349b | |||
| Conservative management | 3 | 6 | |
| Reoperation | 0 | 2 | |
| 0.531b | |||
| Conservative management | 1 | 3 | 0.349b |
| Reoperation | 2 | 5 | |
| 0.999b | |||
| Conservative management | 2 | 3 | |
| Reoperation | 0 | 0 | |
| Urinary tract infection | 4 | 7 | |
| Neobladder stone | 3 | 3 | |
| 2 | 1 | 0.574b | |
| 0 | 0 | 0.999b |
Final pathology outcomes and oncological outcomes in ELRC group versus TLRC group
| Outcomes | ELRC ( | TLRC ( | |
|---|---|---|---|
| Local recurrence | 1 | 3 | 0.636b |
| Distant metastasis | 2 | 2 | 0.999b |
| Cancer-specific mortality for 2 years | 2 | 3 | 0.999b |
| Non-cancer-specific mortality for 2 years | 1 | 1 | 0.999b |
| 0.793a | |||
| pTis Ta | 8 | 12 | |
| pT1 | 17 | 24 | |
| pT2a | 16 | 15 | |
| pT2b | 5 | 10 | |
| pT3a | 2 | 3 | |
| pT3b | _ | 1 | |
| pT4a | _ | _ | |
| pT4b | _ | _ | |
| Lymph node positive (pN+), no. (%) | 2(4.2) | 1(1.5) | 0.574b |
| Lymph node yield, mean ± SD, | 18.9 ± 2.4 | 20.0 ± 2.0 | 0.638c |
| 0.999b | |||
| Positive | 3 (6.3) | 5 (7.7) | |
| Negative | 45 (93.7) | 60 (92.3) |
aPearson chi-square test
bFisher exact test
cIndependent t test
Continence of 113 patients with bladder cancer treated by TLRC versus ELRC
| Variables | Overall ( | ELRC group ( | TLRC group ( | |
|---|---|---|---|---|
| 0–1 pad/day, | 103 (91.2) | 44 (91.7) | 59 (90.8) | 1a |
| > 1 pad/day, | 10 (8.8) | 4 (8.3) | 6 (9.2) | |
| 0–1 pad/day, | 97 (85.8) | 42 (87.5) | 55 (84.6) | 0.788a |
| >1 pad/day, | 16 (14.2) | 6 (12.5) | 10 (15.4) | |
| Neobladder capacity at 12 months, mean ± SD (range), ml | 397.1 ± 80.5 (360–485) | 390.9 ± 77.7 (370–485) | 401.7 ± 94.8 (360–470) | 0.695c |
aPearson chi-square test
bFisher exact test
cIndependent t test